Work

PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.

Year: 2011

Type: article

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs11-pd05-03

Authors: EA Perez, KV Ballman, MM Reinholz, AC Dueck, H Cheng, RB Jenkins, AE McCullough, B Chen, NE Davidson, S Martino, PA Kaufman, LA Kutteh, GW Sledge, XJ Geiger, JN Ingle, KS Tenner, LN Harris, JR Gralow, DL Rimm

Institutions: Dartmouth–Hitchcock Medical Center, Mayo Clinic, Seattle Cancer Care Alliance, Yale University, Angeles Clinic and Research Institute, Mayo Clinic in Arizona, UPMC Hillman Cancer Center, Mayo Clinic in Florida, Indiana University Indianapolis

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2021075165

FWCI:

Cites:

Cited by:

Related to: 10